UNSPSC 51272703: Antrafenine

This classification denotes an anesthetic agent with the molecular formula C30H26F6N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21FS93Y6OE, chemically known as 2-(4-(alpha,alpha,alpha-trifluoro-m-tolyl)-1-piperazinyl)ethyl n-(7-(trifluoromethyl)-4-quinolyl)anthranilate but generally known as antrafenine, which bears US NIH Compound Identifier 68723. European Medicines Agency schedules Antrafenine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05530MIG.

UNSPSC 51272703 Antrafenine is a Commodity code that captures pharmaceutical products procured by state and local health authorities, though recent state and local activity under this specific code shows minimal direct alignment with antrafenine itself. Instead, the code receives solicitations for broader pharmaceutical categories including naloxone, generic multi-source drugs, and over-the-counter products distributed through state and local health systems, community health departments, and cooperative purchasing alliances. Issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). These jurisdictions procure pharmaceuticals for community health initiatives, pharmacy benefit programs, and distribution across participating state and local government facilities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to its Community Health Building in Sanford with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription fulfillment capabilities outside traditional pharmacy benefit manager arrangements. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026, and contract effectiveness July 1, 2026; that procurement weights price competitiveness at 75 percent and imposes a 3 percent administrative fee on all purchases.